By Robert Short
An implantable cardioverter-defibrillator produces better survival rates than does amiodarone therapy in sustained ventricular tachyarrhythmias after heart attack. This conclusion was the result of a study of 84 patients, carried out by Dr J Schläpfer and colleagues at the Division of Cardiology, University Hospital (CHUV), Lausanne, Switzerland.
The patients who had experienced myocardial infarction had a mean left ventricular ejection fraction of about 36 percent. Roughly half the patients were found to be responders to amiodarone therapy.
The non responders were eventually treated with an implantable cardioverter-defibrillator. The investigators found that during a mean follow-up period of 63 months, the sudden cardiac death rate and total mortality rate were significantly higher in the amiodarone-treated patients.
Dr Schläpfer concluded, “The long-term survival of patients with sustained ventricular tachyarrhythmias after myocardial infarction, with depressed left-ventricular function, is significantly better with an implantable cardioverter-defibrillator than with amiodarone therapy.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!